Showing results (131-140 of 160) with videos related to
Sort By:
Pageof 16
Proceedings of the National Academy of Sciences of the United States of America|July 31, 2023
Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumorsTravis P Schrank, Aditi Kothari, William H Weir, et al.Future Oncology (London, England)|June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.Journal for Immunotherapy of Cancer|July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2025
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx CancerBarbara Burtness, Yael Flamand, Harry Quon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q M Chow, Robert Haddad, Shilpa Gupta, et al.Oral Oncology|April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Danny Rischin, Kevin J Harrington, Richard Greil, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV TrialMarcin Dzienis, Juan Cundom, Christian Sebastian Fuentes, et al.Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.Cancer Discovery|November 6, 2012
Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradationAnna Sukhanova, Andrey Gorin, Ilya G Serebriiskii, et al.Circulation Research|October 30, 2012
Cardiotoxic and cardioprotective features of chronic β-adrenergic signalingXiaoying Zhang, Christopher Szeto, Erhe Gao, et al.Pageof 16